The Experts below are selected from a list of 9651 Experts worldwide ranked by ideXlab platform

Tengku-aizan Hamid - One of the best experts on this subject based on the ideXlab platform.

  • The Cochrane Library - Momordica Charantia for type 2 diabetes mellitus
    The Cochrane database of systematic reviews, 2012
    Co-Authors: Cheow Peng Ooi, Zaitun Yassin, Tengku-aizan Hamid
    Abstract:

    Momordica Charantia (bitter gourd) is not only a nutritious vegetable but it is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control. To assess the effects of mormodica Charantia for type 2 diabetes mellitus. Several electronic databases were searched, among these were The Cochrane Library (Issue 1, 2012), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to February 2012), combined with handsearches. No language restriction was used. We included randomised controlled trials (RCTs) that compared Momordica Charantia with placebo or a control intervention, with or without pharmacological or non-pharmacological interventions. Two authors independently extracted data. Risk of bias of the trials was evaluated using the parameters of randomisation, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of Momordica Charantia used in the interventions (no similar preparation was tested twice). Four randomised controlled trials with up to three months duration and investigating 479 participants met the inclusion criteria. Risk of bias of these trials (only two studies were published as a full peer-reviewed publication) was generally high. Two RCTs compared the effects of preparations from different parts of the Momordica Charantia plant with placebo on glycaemic control in type 2 diabetes mellitus. There was no statistically significant difference in the glycaemic control with Momordica Charantia preparations compared to placebo. When Momordica Charantia was compared to metformin or glibenclamide, there was also no significant change in reliable parameters of glycaemic control. No serious adverse effects were reported in any trial. No trial investigated death from any cause, morbidity, health-related quality of life or costs. There is insufficient evidence on the effects of Momordica Charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of Momordica Charantia are needed before RCTs are established to guide any recommendations in clinical practice.

  • Momordica Charantia for type 2 diabetes mellitus.
    The Cochrane database of systematic reviews, 2010
    Co-Authors: Cheow Peng Ooi, Zaitun Yassin, Tengku-aizan Hamid
    Abstract:

    Momordica Charantia is not only a nutritious vegetable, but is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control. To assess the effects of mormodica Charantia for type 2 diabetes mellitus. Several electronic databases were searched, among these The Cochrane Library (issue 4, 2009), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to November 2009), combined with handsearches. No language restriction was used. Randomized controlled trials that compared Momordica Charantia with a placebo or a control intervention with or without pharmacological or non-pharmacological interventions were included. Two authors independently extracted the data. Risk of bias of trials was evaluated using the parameters of randomization, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of Momordica Charantia used in interventions (no similar preparation was tested twice). Three randomised controlled trials with up to three months duration and investigating 350 participants met the inclusion criteria. Risk of bias of these trials (only one study was published as a full peer-reviewed publication) was generally high. Two RCTs compared the effect of preparations from different parts of the Momordica Charantia plants and placebo on the glycemic control in type 2 diabetes mellitus. There was no statistically significant difference compared to placebo. The effects of preparation from the leaves of the plant and glibenclamide were comparable in the third trial. No serious adverse effects were reported in all the trials. There were no documentations of death from any cause, morbidity, (health-related) quality of life and costs. There is insufficient evidence to recommend Momordica Charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of Momordica Charantia are needed before RCTs are established to guide any recommendations in clinical practice.

Cheow Peng Ooi - One of the best experts on this subject based on the ideXlab platform.

  • The Cochrane Library - Momordica Charantia for type 2 diabetes mellitus
    The Cochrane database of systematic reviews, 2012
    Co-Authors: Cheow Peng Ooi, Zaitun Yassin, Tengku-aizan Hamid
    Abstract:

    Momordica Charantia (bitter gourd) is not only a nutritious vegetable but it is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control. To assess the effects of mormodica Charantia for type 2 diabetes mellitus. Several electronic databases were searched, among these were The Cochrane Library (Issue 1, 2012), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to February 2012), combined with handsearches. No language restriction was used. We included randomised controlled trials (RCTs) that compared Momordica Charantia with placebo or a control intervention, with or without pharmacological or non-pharmacological interventions. Two authors independently extracted data. Risk of bias of the trials was evaluated using the parameters of randomisation, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of Momordica Charantia used in the interventions (no similar preparation was tested twice). Four randomised controlled trials with up to three months duration and investigating 479 participants met the inclusion criteria. Risk of bias of these trials (only two studies were published as a full peer-reviewed publication) was generally high. Two RCTs compared the effects of preparations from different parts of the Momordica Charantia plant with placebo on glycaemic control in type 2 diabetes mellitus. There was no statistically significant difference in the glycaemic control with Momordica Charantia preparations compared to placebo. When Momordica Charantia was compared to metformin or glibenclamide, there was also no significant change in reliable parameters of glycaemic control. No serious adverse effects were reported in any trial. No trial investigated death from any cause, morbidity, health-related quality of life or costs. There is insufficient evidence on the effects of Momordica Charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of Momordica Charantia are needed before RCTs are established to guide any recommendations in clinical practice.

  • Momordica Charantia for type 2 diabetes mellitus.
    The Cochrane database of systematic reviews, 2010
    Co-Authors: Cheow Peng Ooi, Zaitun Yassin, Tengku-aizan Hamid
    Abstract:

    Momordica Charantia is not only a nutritious vegetable, but is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control. To assess the effects of mormodica Charantia for type 2 diabetes mellitus. Several electronic databases were searched, among these The Cochrane Library (issue 4, 2009), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to November 2009), combined with handsearches. No language restriction was used. Randomized controlled trials that compared Momordica Charantia with a placebo or a control intervention with or without pharmacological or non-pharmacological interventions were included. Two authors independently extracted the data. Risk of bias of trials was evaluated using the parameters of randomization, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of Momordica Charantia used in interventions (no similar preparation was tested twice). Three randomised controlled trials with up to three months duration and investigating 350 participants met the inclusion criteria. Risk of bias of these trials (only one study was published as a full peer-reviewed publication) was generally high. Two RCTs compared the effect of preparations from different parts of the Momordica Charantia plants and placebo on the glycemic control in type 2 diabetes mellitus. There was no statistically significant difference compared to placebo. The effects of preparation from the leaves of the plant and glibenclamide were comparable in the third trial. No serious adverse effects were reported in all the trials. There were no documentations of death from any cause, morbidity, (health-related) quality of life and costs. There is insufficient evidence to recommend Momordica Charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of Momordica Charantia are needed before RCTs are established to guide any recommendations in clinical practice.

Zaitun Yassin - One of the best experts on this subject based on the ideXlab platform.

  • The Cochrane Library - Momordica Charantia for type 2 diabetes mellitus
    The Cochrane database of systematic reviews, 2012
    Co-Authors: Cheow Peng Ooi, Zaitun Yassin, Tengku-aizan Hamid
    Abstract:

    Momordica Charantia (bitter gourd) is not only a nutritious vegetable but it is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control. To assess the effects of mormodica Charantia for type 2 diabetes mellitus. Several electronic databases were searched, among these were The Cochrane Library (Issue 1, 2012), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to February 2012), combined with handsearches. No language restriction was used. We included randomised controlled trials (RCTs) that compared Momordica Charantia with placebo or a control intervention, with or without pharmacological or non-pharmacological interventions. Two authors independently extracted data. Risk of bias of the trials was evaluated using the parameters of randomisation, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of Momordica Charantia used in the interventions (no similar preparation was tested twice). Four randomised controlled trials with up to three months duration and investigating 479 participants met the inclusion criteria. Risk of bias of these trials (only two studies were published as a full peer-reviewed publication) was generally high. Two RCTs compared the effects of preparations from different parts of the Momordica Charantia plant with placebo on glycaemic control in type 2 diabetes mellitus. There was no statistically significant difference in the glycaemic control with Momordica Charantia preparations compared to placebo. When Momordica Charantia was compared to metformin or glibenclamide, there was also no significant change in reliable parameters of glycaemic control. No serious adverse effects were reported in any trial. No trial investigated death from any cause, morbidity, health-related quality of life or costs. There is insufficient evidence on the effects of Momordica Charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of Momordica Charantia are needed before RCTs are established to guide any recommendations in clinical practice.

  • Momordica Charantia for type 2 diabetes mellitus.
    The Cochrane database of systematic reviews, 2010
    Co-Authors: Cheow Peng Ooi, Zaitun Yassin, Tengku-aizan Hamid
    Abstract:

    Momordica Charantia is not only a nutritious vegetable, but is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control. To assess the effects of mormodica Charantia for type 2 diabetes mellitus. Several electronic databases were searched, among these The Cochrane Library (issue 4, 2009), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to November 2009), combined with handsearches. No language restriction was used. Randomized controlled trials that compared Momordica Charantia with a placebo or a control intervention with or without pharmacological or non-pharmacological interventions were included. Two authors independently extracted the data. Risk of bias of trials was evaluated using the parameters of randomization, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of Momordica Charantia used in interventions (no similar preparation was tested twice). Three randomised controlled trials with up to three months duration and investigating 350 participants met the inclusion criteria. Risk of bias of these trials (only one study was published as a full peer-reviewed publication) was generally high. Two RCTs compared the effect of preparations from different parts of the Momordica Charantia plants and placebo on the glycemic control in type 2 diabetes mellitus. There was no statistically significant difference compared to placebo. The effects of preparation from the leaves of the plant and glibenclamide were comparable in the third trial. No serious adverse effects were reported in all the trials. There were no documentations of death from any cause, morbidity, (health-related) quality of life and costs. There is insufficient evidence to recommend Momordica Charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of Momordica Charantia are needed before RCTs are established to guide any recommendations in clinical practice.

Yi Chuan-zhu - One of the best experts on this subject based on the ideXlab platform.

  • Study on the Acute Toxicity and Genetic Toxicity of Water Extracts from Momordica Charantia
    China Preventive Medicine, 2008
    Co-Authors: Yi Chuan-zhu
    Abstract:

    Objective To determine the acute oral toxicity and genetic toxicity of water extracts from Momordica Charantia,so as to provide experimental basis for its exploitation.Methods Acute toxicity test and genetic toxicity tests,including Ames test,micronucleus test of polychromatic erythrocytes in bone marrow and sperm shape abnormality test in mice,were performed according to GB159193-2003 Procedures and Methods for Toxicological Assessment of Food.Results The acute oral LD50 of water extracts from Momordica Charantia was greater than 21.5 g/kg bw.The genetic toxicity was negative.Conclusion The acute toxicity of water extracts from Momordica Charantia was classified as non-toxic.Genetic toxicity was not found.

Clara Biksan Lau - One of the best experts on this subject based on the ideXlab platform.

  • anti diabetic properties and phytochemistry of Momordica Charantia l cucurbitaceae
    Phytomedicine, 1996
    Co-Authors: Amala Raman, Clara Biksan Lau
    Abstract:

    Summary Unripe fruit, seeds and aerial parts of Momordica Charantia Linn. (Cucurbitaceae) have been used in various parts of the world to treat diabetes. Oral administration of the fruit juice or seed powder causes a reduction in fasting blood glucose and improves glucose tolerance in normal and diabetic animals and in humans. Animal and in vitro data support both insulin secretagogue and insulinomimetic activity of the fruit. However, enhanced insulin levels in vivo in response to its administration have not been observed. Although a wide range of compounds have been isolated from Momordica Charantia , notably steroidal compounds and proteins, the orally active antidiabetic principle has not been adequately identified. A polypeptide, p-insulin, produces hypoglycaemic effects in humans and animals on subcutaneous injection, but oral activity is questionable. Other reported hypoglycaemic principles from Momordica Charantia include the sterol glucoside mixture charantin (fruit) and the pyrimidine nucleoside vicine (seeds). However these are only effective at doses too high to account for all the activity of the plant extract. Principal toxicity of Momordica Charantia in animals is to the liver and reproductive system. These effects have not been reported in humans despite widespread use of the fruit medicinally and as a vegetable.